Table 4 Group differentiated analysis of outcome parameters according to changes in the bone adjusted ratio of muscle volume.
Parameter | Pre-implant (Baseline) | Follow-up (3-Month) | Follow-up (6-Month) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
ΔMuscle, BAR % | < -10 | ≤ 0 | > 0 | > 10 | < -10 | ≤ 0 | > 0 | > 10 | |||
n | 300 | 32 | 113 | 98 | 30 | 45 | 64 | 62 | 29 | ||
p | p | ||||||||||
FEV1, L | .75 | .75 | .80* | .99* | .92* | < 0.001 | .68* | .84* | .89* | .96* | < 0.001 |
RV, L | 5.7 | 5.1* | 4.8* | 4.9* | 4.4* | 0.076 | 4.9* | 4.6* | 4.8* | 4.3* | 0.216 |
IVC, L | 2.2 | 2.3 | 2.3* | 2.7* | 2.7* | 0.293 | 2.2 | 2.4* | 2.9* | 2.7* | < 0.001 |
6MWD, m | 280 | 260 | 295* | 350* | 365* | < 0.001 | 250* | 277 | 400* | 395* | < 0.001 |
CAT score | 27 | 24* | 24* | 22* | 24* | 0.473 | 28* | 27 | 22* | 22* | < 0.001 |
ΔFEV1, L | .03 | .12 | .10 | .26 | < 0.001 | –.09 | .06 | .08 | .31 | < 0.001 | |
ΔFEV1, % | 5.5 | 17.9 | 11.5 | 39.5 | < 0.001 | –11 | 9 | 10.5 | 43 | < 0.001 | |
ΔRV, L | –.8 | –.82 | –.8 | –.85 | 0.509 | –.75 | –.8 | –.9 | –1 | 0.904 | |
ΔRV, % | –15 | –16 | –13 | –17 | 0.198 | –15 | –16 | –16 | –19 | 0.778 | |
ΔIVC, L | .09 | .35 | .23 | .55 | < 0.001 | –.21 | .23 | .28 | .62 | < 0.001 | |
ΔIVC, % | 4.3 | 16.6 | 10 | 28.4 | < 0.001 | –8.7 | 7.9 | 11 | 28.8 | < 0.001 | |
Δ6MWD, m | 14 | 25 | 54 | 110 | < 0.001 | –35 | –5 | 78 | 140 | < 0.001 | |
ΔCAT score | –2 | –2 | –2 | –3.5 | 0.091 | 2 | 1 | –4 | –5.5 | < 0.001 | |